The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.ad Pleural effusion and drug-induced ILD

VI. Pulmonary vasculopathy

VI.g Foreign body pulmonary vasculopathy (Excipient lung disease)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils